<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS132734</article-id><article-id pub-id-type="doi">10.1101/2021.08.10.455737</article-id><article-id pub-id-type="archive">PPR382070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 Spike and human proteins</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nunez-Castilla</surname><given-names>Janelle</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stebliankin</surname><given-names>Vitalii</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baral</surname><given-names>Prabin</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Balbin</surname><given-names>Christian A</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sobhan</surname><given-names>Masrur</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cickovski</surname><given-names>Trevor</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mondal</surname><given-names>Ananda Mohan</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Narasimhan</surname><given-names>Giri</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Chapagain</surname><given-names>Prem</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mathee</surname><given-names>Kalai</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Siltberg-Liberles</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Biological Sciences, College of Arts, Science and Education, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><aff id="A2"><label>2</label>Bioinformatics Research Group (BioRG), Knight Foundation School of Computing and Information Sciences, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><aff id="A3"><label>3</label>Department of Physics, College of Arts, Science and Education, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><aff id="A4"><label>4</label>Machine Learning and Data Analytics Group (MLDAG), Knight Foundation School of Computing and Information Sciences, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><aff id="A5"><label>5</label>Biomolecular Sciences Institute, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><aff id="A6"><label>6</label>Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University; 11200 SW 8<sup>th</sup> St, Miami, 33199, USA</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author. <email>jliberle@fiu.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>13</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="preprint"><day>11</day><month>08</month><year>2021</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><title>Summary</title><p id="P1">SARS-CoV-2 causes COVID-19, a disease curiously resulting in varied symptoms and outcomes, ranging from asymptomatic to fatal. Autoimmunity due to cross-reacting antibodies resulting from molecular mimicry between viral antigens and host proteins may provide an explanation. We computationally investigated molecular mimicry between SARS-CoV-2 Spike and known epitopes. We discovered molecular mimicry hotspots in Spike and highlight two examples with tentative autoimmune potential and implications for understanding COVID-19 complications. We show that a TQLPP motif in Spike and thrombopoietin shares similar antibody binding properties. Antibodies cross-reacting with thrombopoietin may induce thrombocytopenia, a condition observed in COVID-19 patients. Another motif, ELDKY, is shared in multiple human proteins such as PRKG1 and tropomyosin. Antibodies cross-reacting with PRKG1 and tropomyosin may cause known COVID-19 complications such as blood-clotting disorders and cardiac disease, respectively. Our findings illuminate COVID-19 pathogenesis and highlight the importance of considering autoimmune potential when developing therapeutic interventions to reduce adverse reactions.</p></abstract><kwd-group><kwd>vaccine design</kwd><kwd>AlphaFold</kwd><kwd>coronavirus</kwd><kwd>autoantibody</kwd><kwd>molecular dynamics</kwd><kwd>machine learning</kwd><kwd>protein structure comparison</kwd><kwd>COVID-19 complications</kwd><kwd>variant</kwd><kwd>omicron</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">The coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. COVID-19 is an infectious disease whose typical symptoms include fever, cough, shortness of breath (<xref ref-type="bibr" rid="R21">Guan et al., 2020</xref>; <xref ref-type="bibr" rid="R63">Wang et al., 2020</xref>), and loss of taste or smell (<xref ref-type="bibr" rid="R10">Dawson et al., 2021</xref>). Curiously, despite hundreds of millions of confirmed cases worldwide, roughly one third are estimated to be asymptomatic (<xref ref-type="bibr" rid="R46">Sah et al., 2021</xref>). Yet, other SARS-CoV-2 infected individuals may also experience a variety of disease-related complications including liver injury (<xref ref-type="bibr" rid="R49">Saviano et al., 2021</xref>), kidney injury (<xref ref-type="bibr" rid="R22">Han and Ye, 2021</xref>), and cardiovascular complications including myocarditis, heart failure, thrombosis (<xref ref-type="bibr" rid="R34">Long et al., 2020</xref>), and thrombocytopenia (<xref ref-type="bibr" rid="R36">Mei et al., 2020</xref>). COVID-19 can trigger a range of antibody response levels (<xref ref-type="bibr" rid="R67">Wei et al., 2021</xref>) and an enrichment in autoantibodies that react with human proteins has been found for patients with severe disease (<xref ref-type="bibr" rid="R64">Wang et al., 2021</xref>). While the reason for the variety of disease severity affecting people with COVID-19 is not well understood, molecular mimicry may provide an avenue for explanations.</p><p id="P3">Molecular mimicry occurs when unrelated proteins share regions of high molecular similarity, such that they can perform similar and unexpected interactions with other proteins. When molecular mimicry involves antigens to which antibodies are produced, cross-reactive antibodies can result. Molecular mimicry between pathogen antigens and human proteins can cause an autoimmune response, where antibodies against the pathogen erroneously interact with human proteins, sometimes leading to transient or chronic autoimmune disorders (<xref ref-type="bibr" rid="R19">Getts et al., 2013</xref>). Alternatively, molecular mimicry could be viewed through the lens of heterologous immunity, where previous exposure to one pathogen antigen can result in short- or long-term complete or partial immunity to another pathogen with a similar antigen (<xref ref-type="bibr" rid="R1">Agrawal, 2019</xref>). Moreover, antigen-driven molecular mimicry can also lead to cross-reactive antibody immunity which has been reported against SARS-CoV-2 for uninfected individuals (<xref ref-type="bibr" rid="R15">Fraley et al., 2021</xref>).</p><p id="P4">The SARS-CoV-2 Spike protein is responsible for enabling SARS-CoV-2 entry into host cells (<xref ref-type="bibr" rid="R52">Shang et al., 2020</xref>). Spike protrudes from the virus surface and is one of the main antigenic proteins for this virus (<xref ref-type="bibr" rid="R62">Voss et al., 2021</xref>). Additionally, Spike is the primary component in the vaccines against SARS-CoV-2. Consequently, mimicry between Spike and human proteins or Spike and other human pathogens can result in cross-reactive antibodies in response to SARS-CoV-2 infection or vaccination. Cross-reactive antibodies may yield complex outcomes such as diverse symptoms with varying severity across populations and developmental stages as observed for COVID-19. Identifying autoimmune potential and heterologous immunity through instances of molecular mimicry between Spike and proteins from humans or human pathogens can serve to better understand disease pathogenesis, improve therapeutic treatments, and inform vaccine design as they relate to SARS-CoV-2 infection. We set out to investigate molecular mimicry between Spike and known epitopes from the Immune Epitope Database (IEDB) (<xref ref-type="bibr" rid="R61">Vita et al., 2019</xref>). We define molecular mimicry as a match of at least 5 identical consecutive amino acids that appear in both Spike and in a known epitope, where at least 3 amino acids are surface accessible on Spike and the match from the epitope has high structural similarity to the corresponding sequence from Spike. In light of our findings, we discuss autoimmune potential and heterologous immunity with implications for vaccine design and the side-effects of SARS-CoV-2 infection.</p></sec><sec id="S2" sec-type="results | discussion"><title>Results and Discussion</title><p id="P5">We used Epitopedia (<xref ref-type="bibr" rid="R3">Balbin et al., 2021</xref>) to predict molecular mimicry for the structure of the SARS-CoV-2 Spike protein (PDB id: 6XR8, chain A (<xref ref-type="bibr" rid="R6">Cai et al., 2020</xref>)) against all linear epitopes in IEDB, excluding those from Coronaviruses. Epitopedia returned 789 sequence-based molecular mimics (termed as “1D-mimics”). 1D-mimics are protein regions from epitopes that share at least five consecutive amino acids with 100% sequence identity to a pentapeptide in SARS-CoV-2 Spike, where at least three of the amino acids are surface accessible on Spike. Most 1D-mimics (627 epitopes) were found in human. Additionally, 1D-mimics were found in non-human vertebrates (65 epitopes, 7 species), viruses (58 epitopes, 17 species), bacteria (18 epitopes, 7 species), parasitic protists (12 epitopes, 2 species), plants (5 epitopes, 2 species), and invertebrates (4 epitopes, 2 species). Seemingly redundant 1D-mimics from the same protein may represent different epitopes and, thus, all 789 1D-mimics were kept at this step.</p><p id="P6">Structural representatives from the Protein Data Bank (PDB) were identified for 284 1D-mimics based on their source sequence using the minimum cutoffs of 90% for sequence identity and 20% for query cover. The 284 1D-mimics are represented by 7,992 redundant structures from 1,514 unique PDB chains. From these, structure-based molecular mimics (termed as “3D-mimics”) were identified. 3D-mimics are 1D-mimics that share structural similarity with SARS-CoV-2 Spike as determined by an RMSD of at most 1 Å. We found 20 3D-mimics for Spike. Unsurprisingly, as with the 1D-mimics, most 3D-mimics were found for human proteins. Additionally, one 3D-mimic was found for <italic>Mus musculus</italic> (mouse), <italic>Mycobacterium tuberculosis, Phleum pratense</italic> (Timothy grass), and respiratory syncytial virus, respectively (<xref ref-type="table" rid="T1">Table 1</xref>). For each 3D-mimic, Epitopedia computes a Z-score based on the distribution of RMSD values for all resulting hits for the input structure. This allows for a comparative assessment of the quality of a hit, with respect to RMSD, to other hits for a given run. Epitopedia also computes an EpiScore for each hit. EpiScore, calculated as (<italic>motif length / RMSD</italic>), favors longer motifs over shorter ones with the same RMSD values.</p><p id="P7">For the 402 human 1D-mimics where no PDB structural representative could be identified for their source sequence, AlphaFold2 3D models were used. 3D model representatives were found for 102 human 1D-mimics. Of these, 10 are predicted to be AF-3D-mimics based on the RMSD (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p id="P8">The 3D- and AF-3D-mimics (hereinafter referred to as “molecular mimics”) mapped to a few clusters on Spike. Ten molecular mimics were singletons, six overlapping molecular mimics were found as pairs in three small clusters, and the remaining 14 were found in three larger clusters with at least four overlapping molecular mimics (<xref ref-type="fig" rid="F1">Figure 1a</xref>). The largest cluster, with six molecular mimics, was also adjacent to three additional molecular mimics. All mimics are displayed on the surface of Spike’s functional trimer, but the large cluster centered around LLLQY is in a deep pocket and is an unlikely antibody binding epitope in this conformation (<xref ref-type="fig" rid="F1">Figure 1b</xref>). To further evaluate the autoimmune potential of the human mimics, we identified all occurrences of the motifs in the human RefSeq Select proteome (“NCBI RefSeq Select,” n.d.). The pentapeptides from the molecular mimicry regions are found from four to 33 times in human proteins (<xref ref-type="fig" rid="F1">Figure 1c</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). The human protein thrombopoietin that includes the 3D-mimic TQLPP (<xref ref-type="table" rid="T2">Table 2</xref>) also has an occurrence of the sequence mimic LPDPS (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Further, another protein family that occurs twice for the same pentapeptide is tropomyosin. Tropomyosin alpha-3 is an AF-3D-mimic (<xref ref-type="supplementary-material" rid="SD1">Table 3</xref>), and tropomyosin alpha-1 has one occurrence of the same pentapeptide (ELDKY). The same motif, ELDKY, is a 3D-mimic in the fusion F0 glycoprotein of respiratory syncytial virus (<xref ref-type="table" rid="T2">Table 2</xref>). Altogether, based on the known epitopes in IEDB, heterologous immunity is rare with Spike while the autoimmune potential resembles hotspots.</p><p id="P9">To further evaluate molecular mimicry and, indirectly, autoimmune potential, we performed a deeper investigation of two motifs, TQLPP and ELDKY, that mapped to positions 22-26 (small cluster) and 1151-1155 (largest cluster) in Spike, respectively. For TQLPP, a 3D-mimic with human thrombopoietin was identified. The only structure in our dataset where a 3D-mimic was located at an antibody interface was for human thrombopoietin (hTPO). Thrombopoietin is a cytokine that regulates platelet production (<xref ref-type="bibr" rid="R60">Varghese et al., 2017</xref>) (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>). Interestingly, COVID-19 patients often suffer from thrombocytopenia, characterized by low platelet levels (<xref ref-type="bibr" rid="R71">Yang et al., 2020</xref>), which correlates with an almost 5-fold increase in mortality (<xref ref-type="bibr" rid="R53">Shi et al., 2021</xref>). Thrombocytopenia in COVID-19 patients resembles immune thrombocytopenia, where hTPO and/or its receptor are mistakenly targeted by autoantibodies leading to reduced platelet count (<xref ref-type="bibr" rid="R37">Nazy et al., 2018</xref>). Treatments with hTPO Receptor Agonists improve thrombocytopenia in both general (<xref ref-type="bibr" rid="R2">Audia and Bonnotte, 2021</xref>) and COVID-19 (<xref ref-type="bibr" rid="R66">Watts et al., 2021</xref>) patients, suggesting the mistaken targeting occurs before hTPO activates the hTPO receptor. For ELDKY, we identified one 3D-mimic in the fusion F0 glycoprotein of respiratory syncytial virus (<xref ref-type="table" rid="T2">Table 2</xref>) and two AF-3D-mimics from keratin type I cytoskeletal 18 and tropomyosin alpha-3 (<xref ref-type="supplementary-material" rid="SD1">Table 3</xref>). Additional 3D-mimics partially overlapping with ELDKY were identified. The ELDKY motif in Spike is found in an α-helix located towards the C-terminus. This motif is conserved across beta-coronaviruses and can bind an antibody effective against all human-infecting beta-coronaviruses (<xref ref-type="bibr" rid="R43">Pinto et al., 2021</xref>). Altogether, the numerous molecular mimics of the ELDKY motif suggests a potential for both protective and autoimmune cross-reactivity.</p><sec id="S3"><title>Molecular mimicry between Spike and Thrombopoietin mediated through TQLPP</title><p id="P10">The shared five-amino acid motif, TQLPP (<xref ref-type="fig" rid="F2">Figure 2a</xref>), is located on the surface of Spike’s N-terminal Domain (NTD) (<xref ref-type="fig" rid="F2">Figure 2b, c</xref>), whereas it is found at the interface with a neutralizing antibody in hTPO (<xref ref-type="bibr" rid="R13">Feese et al., 2004</xref>) (<xref ref-type="fig" rid="F2">Figure 2d</xref>). The TQLPP motifs from the two proteins are found in coil conformations but exhibit high structural similarity (<xref ref-type="fig" rid="F2">Figure 2e, f</xref>). On Spike, the motif is adjacent to the NTD supersite that is known to be targeted by neutralizing antibodies (<xref ref-type="bibr" rid="R7">Cerutti et al., 2021</xref>). We hypothesized that COVID-19 may trigger the production of TQLPP-specific antibodies against this epitope that can cross-react with hTPO. In the absence of Spike TQLPP antibodies, we used molecular modeling and machine learning to investigate the binding of the neutralizing mouse Fab antibody (TN1) from the hTPO structure (<xref ref-type="bibr" rid="R57">Tahara et al., 1998</xref>) to the Spike TQLPP epitope.</p><p id="P11">To construct a composite model of Spike and TN1 Fab, a full-length glycosylated model of the Spike trimer, based on PDB id 6VSB (<xref ref-type="bibr" rid="R69">Wrapp et al., 2020</xref>) with the first 26 residues (including the TQLPP motif) reconstructed (<xref ref-type="bibr" rid="R68">Woo et al., 2020</xref>), was coupled to three copies of TN1 Fab from the structure of hTPO complexed with TN1 Fab (<xref ref-type="bibr" rid="R13">Feese et al., 2004</xref>). The Spike-TN1 complex was energy minimized and equilibrated with molecular dynamics (MD) simulation. The final model of the Spike trimer complexed with three TN1 Fab antibodies (<xref ref-type="fig" rid="F3">Figure 3a, b</xref>) shows that the TQLPP epitope is accessible to the antibody and the adjacent glycan chains do not shield the antibody-binding site (<xref ref-type="fig" rid="F3">Figure 3c</xref>, <xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>). To confirm the conformation of TQLPP, we calculated the RMSD for TQLPP regions from 60 Spike proteins from PDB, plus the modeled states (before and after equilibration, and upon 200 ns MD simulation) in an all-vs-all manner (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>). The reconstructed TQLPP region falls within the conformational ensemble from PDB, suggesting that the modeled representation of TQLPP is valid.</p><p id="P12">To evaluate the molecular mimicry between the antibody interface areas, we performed MD simulations of hTPO and Spike NTD with TQLPP complexed with the TN1 antibody. The hydrogen bonds were calculated between the TN1 antibody with hTPO and Spike, respectively, from the last 50 ns of both trajectories (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). Both the Spike-TN1 and the hTPO-TN1 complexes showed similar contact areas (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). Notably, critical hydrogen bonds were observed for residues Q and L in the TQLPP motif with TN1 for both Spike and hTPO (<xref ref-type="fig" rid="F3">Figure 3d, e</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>).</p><p id="P13">To further support our findings, we evaluated the antibody-antigen interface complementarity with MaSIF-search, a recent tool that uses deep learning techniques (<xref ref-type="bibr" rid="R18">Gainza et al., 2019</xref>), on a pair of circular surface regions (patches) from an antibody-antigen complex. MaSIF-search produces a score associated with the strength of binding when forming a stable complex. Lower scores are associated with stronger binding. We refer to this score here as the binding score. The results show that Spike-TN1 complexes have a better (lower) binding score than random complexes and that complexes including Spike from PDB ID 7LQV (<xref ref-type="bibr" rid="R7">Cerutti et al., 2021</xref>) have three of the four best binding scores (0.86, 1.05, 1.42) and may bind to TN1 as well as, or better than, hTPO (<xref ref-type="fig" rid="F3">Figure 3h</xref>, <xref ref-type="supplementary-material" rid="SD1">Tables S4-5</xref>). Notably, in 7LQV, COVID-19 antibodies bind to Spike at the NTD supersite (<xref ref-type="bibr" rid="R7">Cerutti et al., 2021</xref>). These results strongly argue for the possibility of cross-reactivity between Spike and hTPO driven by the molecular mimicry of TQLPP (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p><p id="P14">The human proteome contains nine additional occurrences of the TQLPP motif. Two of these motifs, found in Hermansky-Pudlak syndrome 4 protein and ALG12 (Mannosyltransferase ALG12 homolog), have been associated with thrombosis and hemostasis disorder (<xref ref-type="bibr" rid="R28">Kanduc, 2021</xref>). To evaluate structural mimicry between Spike-TQLPP and all human-TQLPP motifs, we utilized AlphaFold2 3D models (<xref ref-type="bibr" rid="R27">Jumper et al., 2021</xref>; <xref ref-type="bibr" rid="R59">Tunyasuvunakool et al., 2021</xref>) (<xref ref-type="supplementary-material" rid="SD1">Figure S5</xref>). The closest structural mimicry region is in hTPO (RMSD = 0.39 Å), followed by coiled-coil domain-containing protein 185, Fc receptor-like protein 4 (FCRL4), and far upstream element-binding protein 1 (<xref ref-type="supplementary-material" rid="SD1">Figure S5</xref>). These results indicate that TQLPP motifs have similar conformations (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>), strengthening the notion of structural mimicry. We investigated the potential cross-reactivity of an antibody targeting TQLPP in these proteins, after discarding six that display the TQLPP motif in low confidence or unstructured regions. The remaining three proteins, NEK10 (ciliated cell-specific kinase), FCRL4, and ALG12 were complexed with TN1 (<xref ref-type="fig" rid="F4">Figure 4</xref>). The binding score for NEK10-TN1 (1.44) is comparable to the hTPO-TN1 complex (<xref ref-type="fig" rid="F4">Figure 4</xref>). NEK10 regulates motile ciliary function responsible for expelling pathogens from the respiratory tract (<xref ref-type="bibr" rid="R8">Chivukula et al., 2020</xref>). Dysfunction of NEK10 can impact mucociliary clearance and lead to respiratory disorders such as bronchiectasis (<xref ref-type="bibr" rid="R8">Chivukula et al., 2020</xref>). Based on our results, it is plausible that the function of NEK10 and thus mucociliary clearance can be affected by cross-reactive Spike antibodies targeting TQLPP.</p></sec><sec id="S4"><title>Molecular mimicry between Spike, RSV, and many human proteins mediated through ELDKY</title><p id="P15">Another motif, ELDKY, is in a region with several partially overlapping pentamer motifs including three 3D-mimics and three AF-3D-mimics (<xref ref-type="fig" rid="F5">Figure 5a</xref>). For the 3D-mimics, two are from the human proteins kynureninase (hKYNU; motif: EELDK) and cytoplasmic FMR1-interacting protein 1 (hCYFIP1; motif: DKYFK), while the last is found in the fusion F0 glycoprotein of respiratory syncytial virus (RSV; motif: ELDKY). For the AF-3D-mimics, the motif is found in human tight junction-associated protein 1 (hTJAP1; motif: EELDK), keratin type I cytoskeletal 18 (hkRT18; motif: EELDKY), and tropomyosin alpha-3 (hTPM3; motif: ELDKY). In Spike, the ELDKY motif is in a stem helix region near the C-terminus. This motif is well-conserved across beta-coronaviruses and has been shown to bind to a broadly neutralizing antibody effective against all human-infecting beta-coronaviruses (<xref ref-type="bibr" rid="R43">Pinto et al., 2021</xref>). Additionally, stronger antibody responses to the epitope containing the ELDKY motif have been recorded for severe (requiring hospitalization) vs moderate cases, while fatal cases had a weaker response than surviving cases (<xref ref-type="bibr" rid="R62">Voss et al., 2021</xref>). Together with the 3D-mimics identified here, these results suggest interesting possibilities for the ELDKY motif from the perspective of both protective immunity and an autoimmune response. First, while not an example of molecular mimicry, prior exposure to an endemic cold-causing coronavirus (ex. HCoV-OC43) could result in the production of a broadly neutralizing antibody against an epitope containing the ELDKY motif that would be effective against SARS-CoV-2 infection, which could result in milder or asymptomatic infection. Further, a protective effect due to molecular mimicry is suggested by the 3D-mimic identified for the fusion F0 glycoprotein of RSV, a common virus that infects most children in the United States by the time they are 2 years old (“Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious Diseases,” n.d.), where antibodies against the ELDKY-containing epitope in RSV may be effective in combatting SARS-CoV-2 infection. In contrast, the potential for an autoimmune response against this motif is suggested by its presence in both two human 3D- and AF-3D-mimics (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p><p id="P16">There are six additional occurrences of the ELDKY motif in the human proteome (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>). Structural similarity between Spike-ELDKY and human-ELDKY was assessed based on experimentally determined structures (if available) or AlphaFold2 3D models. RMSDs for the ELDKY motif ranged from 0.12-0.20 Å for 5 of the structures, with one hit being an outlier at an RMSD = 0.46 Å. In all instances, the ELDKY motif is found in an α-helix, resulting in the high degree of structural similarity found for this motif across proteins and bolstering the possibility for molecular mimicry. The ELDKY occurrence with the largest RMSD (0.46 Å) is found in the leucine-zipper dimerization domain of cGMP-dependent protein kinase 1 (PRKG1) (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>) whose phosphorylation targets have roles in the regulation of platelet activation and adhesion (<xref ref-type="bibr" rid="R33">Li et al., 2003</xref>), smooth muscle contraction (<xref ref-type="bibr" rid="R48">Sauzeau et al., 2000</xref>), and cardiac function (<xref ref-type="bibr" rid="R16">Francis, 2010</xref>). Additionally, PRKG1 regulates intracellular calcium levels via a multitude of signaling pathways (<xref ref-type="bibr" rid="R16">Francis et al., 2010</xref>). The ELDKY motif is also found in tropomyosin alpha-1 (TPM1), a homolog of the AF-3D-mimic tropomyosin alpha-3 (TPM3). Tropomyosins (TPMs) are involved in regulation of the calcium-dependent contraction of striated muscle (<xref ref-type="bibr" rid="R56">Szent-Györgyi, 1975</xref>). TPM1 is a 1D-mimic but due to a discrepancy in IEDB it was not identified as a 3D-mimic, although there is high structural similarity between ELDKY in Spike and ELDKY in TPM1 (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>). A previous study identified a longer match with 53% sequence identity between Spike and TPM1 that included the ELDKY motif but was not able to show the structural similarity (<xref ref-type="bibr" rid="R35">Marrama et al., 2022</xref>) due to using a structure for Spike that did not include the ELDKY motif. Cross-reactive Spike antibodies targeting ELDKY may react with PRKG1, affecting its role in the regulation of platelet activation and adhesion and thus providing another avenue for thrombocytopenia or other blood clotting disorders. Antibodies that cross-react with PRKG1 may also alter calcium levels, thus affecting TPM function. For TPM1, cross-reactive Spike antibodies targeting the ELDKY motif may result in coronary heart disease, as low-level autoantibodies against this protein have been associated with increased risk for this condition (<xref ref-type="bibr" rid="R73">Zhang et al., 2020</xref>) and TPM1 and TPM3 are cardiac disease-linked antigens (<xref ref-type="bibr" rid="R35">Marrama et al., 2022</xref>). Cardiac disease, including myocardial injury and arrhythmia, can be induced by SARS-CoV-2 infection (<xref ref-type="bibr" rid="R39">Nishiga et al., 2020</xref>) and myocarditis has been found to develop in some individuals following vaccination against SARS-CoV-2 (<xref ref-type="bibr" rid="R41">Patone et al., 2021</xref>). Furthermore, COVID-19 has been found to increase risk and long-term burden of several cardiovascular diseases, with COVID-19 severity being proportionate to increased risk and incidence. (<xref ref-type="bibr" rid="R70">Xie et al., 2022</xref>).</p></sec></sec><sec id="S5" sec-type="conclusions"><title>Conclusion</title><p id="P17">We find that molecular mimics with high autoimmune potential are often found in clusters within Spike. Some clusters have several molecular mimics whose motifs are also found multiple times in the human proteome. Molecular mimics located in α-helices tend to have high structural similarity as can be expected based on the regular conformation of the helix, but also some molecular mimics in coil regions are remarkably similar. Our results on the TQLPP motif, located in a coil region, suggest a worrisome potential for cross-reactivity due to molecular mimicry between Spike and hTPO involving the TQLPP epitope that may affect platelet production and lead to thrombocytopenia. Further, cross-reactivity with other TQLPP-containing proteins such as NEK10 cannot be dismissed based on our in-silico results, but in-vivo validation is required. The presence of neutralizing antibodies against peptides with TQLPP in COVID-19 patients’ convalescent plasma (<xref ref-type="bibr" rid="R32">Li et al., 2020</xref>), particularly in severe and fatal cases (<xref ref-type="bibr" rid="R62">Voss et al., 2021</xref>) adds credence to our result. It is also interesting to note that antibodies against a TQLPP-containing peptide were found in the serum of pre-pandemic, unexposed individuals (<xref ref-type="bibr" rid="R55">Stoddard et al., 2021</xref>). Prior infection with a different human coronavirus cannot explain the cross-reactivity observed in the unexposed group because TQLPP is situated in a region with low amino acid conservation (<xref ref-type="bibr" rid="R55">Stoddard et al., 2021</xref>). Rather, this suggests the presence of an antibody for an unknown epitope with affinity for the TQLPP region in Spike. The COVID-19 vaccines designed to deliver the Spike protein from SARS-CoV-2, like COVID-19 infection itself, can cause thrombocytopenia (<xref ref-type="bibr" rid="R20">Greinacher et al., 2021</xref>; <xref ref-type="bibr" rid="R23">Helms et al., 2021</xref>; <xref ref-type="bibr" rid="R51">Schultz et al., 2021</xref>; <xref ref-type="bibr" rid="R71">Yang et al., 2020</xref>) and it is plausible that cross-reactivity can titrate the serum concentration of free hTPO. The evolutionary trends in the TQLPP motif suggested it may not remain in Spike. In the Gamma variant, a P26S mutation has changed TQLPP to TQLPS and two additional mutations are located just before the motif at L18F and T20N in the NTD supersite, while the Delta variant is mutated at T19R (<xref ref-type="bibr" rid="R24">Hodcroft, 2021</xref>). The first Omicron variant (21K or BA.1), however, has no amino acid substitutions near the TQLPP motif, while a closely related Omicron variant (21L or BA.2) contains a 9 nucleotide deletion that results in the loss of 60% of the TQLPP motif (L24-, P25-, P26-) (<xref ref-type="bibr" rid="R24">Hodcroft, 2021</xref>). Neutralizing antibodies targeting the NTD supersite may rapidly lose efficacy against the evolving SARS-CoV-2. Consequently, protein engineering of the TQLPP motif and possibly the NTD supersite for future COVID-19 vaccines may reduce the risk for thrombocytopenia and improve long-term vaccine protection against evolving variants.</p><p id="P18">We illuminated the cross-reactivity mediated through the ELDKY motif between Spike and PRKG1, TPM1, and TPM3. While PRKG1 provides a connection between blood clotting disorders and cardiac complications, it has a larger RMSD than other ELDKY motifs. ELDKY motifs in α-helices have high similarity and make good candidates for molecular mimicry. We find ELDKY in the homologous proteins TPM1 and TPM3 suggesting a conserved importance for structure and function. In contrast to TQLPP, the ELDKY motif is highly conserved among beta-coronaviruses (<xref ref-type="bibr" rid="R43">Pinto et al., 2021</xref>) and there are presently no SARS-CoV-2 variants with mutations in this region (<xref ref-type="bibr" rid="R24">Hodcroft, 2021</xref>). Further, while the existence of a broadly neutralizing antibody against an epitope containing ELDKY (<xref ref-type="bibr" rid="R43">Pinto et al., 2021</xref>) illustrates the potential of this motif as a pan-coronavirus vaccine target, the viability may be diminished by the possibility for autoimmune cross-reactivity due to this motif.</p><p id="P19">We present an extended application of Epitopedia (<xref ref-type="bibr" rid="R3">Balbin et al., 2021</xref>) to identify molecular mimicry between Spike and known epitopes. We do not attempt to discover all possible epitopes for Spike but focus on epitopes with positive assays from the IEDB (<xref ref-type="bibr" rid="R61">Vita et al., 2019</xref>). For one epitope, we find the TQLPP motif and an interacting antibody with which we perform a computational investigation into antibody binding properties of the tentative molecular mimic. The results show that the same antibody may be able to bind TQLPP-containing epitopes in different proteins and that the TQLPP motif tends to be found in similar conformations despite being in a loop or coil. For another epitope, we find the ELDKY motif with potential for protective immunity and with high structural similarity. High structural similarity can be expected for α-helical structures, and, if the sequence is identical, molecular mimicry results. Altogether, these are examples of molecular mimicry that may play a role in autoimmune or cross-reactive potential of antibodies generated by the immune system against SARS-CoV-2 Spike, but it must be noted that these results have not been experimentally verified. Still, computational investigations into the autoimmune potential of pathogens like SARS-CoV-2 are important for therapeutic intervention and when designing vaccines to avoid potential predictable autoimmune interference.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><sec id="S7"><title>Identifying epitopes with molecular mimicry</title><p id="P20">To identify known epitopes with positive assays, we used Epitopedia (<xref ref-type="bibr" rid="R3">Balbin et al., 2021</xref>) with a Cryo-EM structure of Spike from SARS-CoV-2 (PDB id: 6XR8, chain A (<xref ref-type="bibr" rid="R6">Cai et al., 2020</xref>)) as input. Hits containing 5 or more consecutive residues with 100% sequence identity where at least 3 of the input residues are surface accessible are considered sequence-based molecular mimics (termed as “1D-mimics”). For all 1D-mimics with corresponding structural representation from either PDB (<xref ref-type="bibr" rid="R4">Berman et al., 2000</xref>) or AlphaFold2 (<xref ref-type="bibr" rid="R59">Tunyasuvunakool et al., 2021</xref>) 3D models of human proteins, TM-align (<xref ref-type="bibr" rid="R72">Zhang and Skolnick, 2005</xref>) was used to generate a structural alignment and Root Mean Square Deviation (RMSD) for all input-hit (1D-mimic) alignment pairs using only the structural regions corresponding to the hit for the source antigenic protein containing the epitope and the input. Epitopes with an RMSD ≤ 1 Å to Spike were considered structure-based molecular mimics (termed as “3D-mimics”).</p></sec><sec id="S8"><title>Conformational ensemble of TQLPP structural mimicry</title><p id="P21">To gather all structures of the TQLPP motif in Spike, an NCBI BLASTP search against PDB was performed with the SARS-CoV-2 Spike reference sequence as the query and a SARS-CoV-2 taxa filter. Of 75, close to full-length, hits (&gt;88% query cover), 20 included a solved structure for the TQLPP motif. The TQLPP region of the PDB structure was extracted for all chains in the 20 structures (all were trimers, as in Spike’s biological state) resulting in a TQLPP Spike ensemble of 60 different chains from SARS-CoV-2. Each sequence in the TQLPP Spike ensemble was superimposed with chain X of the two PDB structures of human thrombopoietin (hTPO, PDB ids: 1V7M and 1V7N) to generate an RMSD value distribution for Spike’s conformational ensemble vs hTPO for the structural mimicry region (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>).</p></sec><sec id="S9"><title>Modeling Spike-TN1 complex</title><p id="P22">We constructed a composite model of the Spike-TN1 complex using the hTPO-TN1 complex (PDB id: 1V7M) as a template. For this, we first aligned the TQLPP segment of hTPO in the hTPO-TN1 complex with the TQLPP segment of the fully glycosylated model of Spike (PDB id: 6VSB (<xref ref-type="bibr" rid="R69">Wrapp et al., 2020</xref>)) retrieved from the CHARMM-GUI Archive (<xref ref-type="bibr" rid="R9">Choi et al., 2021</xref>). We then removed hTPO, leaving TN1 complexed with Spike. For the Spike-TN1 simulations, only the TN1 interacting N-terminal domain of Spike (residues 1-272) was considered. Geometrical alignments, as well as visualization, were performed with PyMOL version 2.5 (<xref ref-type="bibr" rid="R50">Schrödinger, 2015</xref>) and Visual Molecular Dynamics (VMD 1.9.3 (<xref ref-type="bibr" rid="R25">Humphrey et al., 1996</xref>)).</p><p id="P23">To confirm that the modeled Spike TQLPP region is in agreement with the TQLPP region of solved Spike structures, these regions were extracted. TM-align was used to superimpose the TQLPP regions from the different structures, including the modeled TQLPP region from the Spike-TN1 complex, and to calculate the respective RMSD values. Three states of the model were included (before and after equilibration, and after molecular dynamics (described in the following paragraph)) together with the 60 experimentally determined Spike structures in <xref ref-type="supplementary-material" rid="SD1">Table S2</xref> and compared in an all-against-all manner (<xref ref-type="supplementary-material" rid="SD1">Figure S3, Table S3</xref>).</p></sec><sec id="S10"><title>Molecular dynamics simulation</title><p id="P24">A simulation system for the modeled Spike-TN1 complex was prepared using CHARMM-GUI (<xref ref-type="bibr" rid="R5">Brooks et al., 2009</xref>; <xref ref-type="bibr" rid="R26">Jo et al., 2008</xref>; <xref ref-type="bibr" rid="R31">Lee et al., 2016</xref>). The complex was solvated using a TIP3P water model and 0.15 M concentration of KCl and equilibrated for 1 ns at 303 K. All-atom simulations were performed with NAMD2.14 (<xref ref-type="bibr" rid="R42">Phillips et al., 2005</xref>) using CHARMM36m force-field. The production runs were performed under constant pressure of 1 atm, controlled by a Nose-Hoover Langevin piston (<xref ref-type="bibr" rid="R40">Nosé and Klein, 1983</xref>) with a piston period of 50 fs and a decay of 25 fs to control the pressure. The temperature was set to 303 K and controlled by Langevin temperature coupling with a damping coefficient of 1/ps. The Particle Mesh Ewald method (PME) (<xref ref-type="bibr" rid="R12">Essmann et al., 1995</xref>) was used for long-range electrostatic interactions with periodic boundary conditions and all covalent bonds with hydrogen atoms were constrained by Shake (<xref ref-type="bibr" rid="R45">Ryckaert et al., 1977</xref>). The contact area of the interface was calculated as (S1+S2-S12)/2, where S1 and S2 represent the solvent accessible surface areas of the antigen and antibody and S12 represents that for the complex (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). We performed MD simulations of the hTPO-TN1 complexes (PDB ids: 1V7M and 1V7N) as well as the Spike-TN1 complexes modeled from PDB ids: 1V7M and 1V7N to generate interaction matrices of protein-antibody hydrogen bonds during the last 50 ns of 200 ns MD simulation for each run.</p></sec><sec id="S11"><title>Antibody interface complementarity</title><p id="P25">We used the MaSIF-search geometric deep learning tool designed to uncover and learn from complementary patterns on the surfaces of interacting proteins (<xref ref-type="bibr" rid="R18">Gainza et al., 2019</xref>). Surface properties of proteins are captured using radial patches. A radial patch is a fixed-sized geodesic around a potential contact point on a solvent-excluded protein surface (<xref ref-type="bibr" rid="R47">Sanner et al., 1996</xref>). In MaSIF-search, the properties include both geometric and physicochemical properties characterizing the protein surface (<xref ref-type="bibr" rid="R18">Gainza et al., 2019</xref>). This tool exploits that a pair of patches from the surfaces of interacting proteins exhibit interface complementarity in terms of their geometric shape (e.g., convex regions would match with concave surfaces) and their physicochemical properties. The data structure of the patch is a grid of 80 bins with 5 angular and 16 radial coordinates and ensures that its description is rotation invariant. Each bin is associated with 5 geometric and chemical features: shape index, distance-dependent curvature, electrostatics, hydropathy, and propensity for hydrogen bonding. The model converts patches into 80-dimensional descriptor vectors, such that the Euclidian distance between interacting patches is minimized. Here, we define the binding score as a measure of distance between the descriptor vectors of the two patches. Thus, lower “MaSIF binding scores” represent better complementarity and therefore better matches. The pre-trained MaSIF-search model “sc05” with a patch radius of 12 Å was used.</p><p id="P26">Using the MaSIF protocol, we evaluated complexes of the TN1 antibody bound to Spike in the TQLPP region. The antibody-antigen patch pairs were extracted using scripts from the molecular mimicry search pipeline EMoMiS (<xref ref-type="bibr" rid="R54">Stebliankin et al., 2022</xref>). To accommodate multiple Spike configurations, we extracted patches from 40 SARS-CoV-2 Spike-antibody complexes from the SabDab structural antibody database (<xref ref-type="bibr" rid="R11">Dunbar et al., 2014</xref>). Patches centered at Q23 from Spike and W33 from TN1 were selected as representative pairs for the Spike-TN1 interaction type because this potential contact point has the most hydrogen bonds in the modeled Spike-TN1 TQLPP region. Binding scores of randomly formed complexes (Random), complexes between Spike and its native antibodies (Spike-Ab), and complexes between hTPO and TN1 (hTPO-TN1) were extracted and tabulated (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). The distribution of binding scores from randomly formed complexes was obtained by pairing patches from random locations on Spike with patches from its antibodies. For native antibody-antigen Spike-Ab and hTPO-TN1 complexes, we obtained patch pairs from known interface regions using the MaSIF-search strategy for the selection of interacting patches (<xref ref-type="bibr" rid="R18">Gainza et al., 2019</xref>). Columns “Contact AB” and “Contact AG” in <xref ref-type="supplementary-material" rid="SD1">Table S4</xref> indicate the residue used as the center of the patch from the antibody and the corresponding antigen.</p></sec><sec id="S12"><title>Evaluating further cross-reactivity</title><p id="P27">All 3D-mimics and AF-3D-mimics were split into pentapeptides (if mimicry motif exceeded 5 residues) which were used as queries for NCBI BLASTP searches against the RefSeq Select (“NCBI RefSeq Select,” n.d.) set of proteins from the human proteome. Results for the BLAST searches can be found in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>.</p><p id="P28">For the TQLPP sequence motif, 10 representative isoforms in proteins containing the complete motif were found, including hTPO. The other 9 proteins lacked a solved structure containing TQLPP. However, AlphaFold2 3D models were available for all 10 of these RefSeq Select sequences (<xref ref-type="bibr" rid="R27">Jumper et al., 2021</xref>; <xref ref-type="bibr" rid="R59">Tunyasuvunakool et al., 2021</xref>), allowing us to extract the region corresponding to TQLPP in these hits and structurally superimpose this region with Spike TQLPP (from PDB id 6XR8) with TM-align as described above.</p><p id="P29">TN1-protein complexes were generated for three of the remaining 9 proteins (Fc receptor-like protein 4 (residues 190-282), serine/threonine-protein kinase NEK10 (residues 1029-1146), ALG12 (Mannosyltransferase ALG12 homolog (residues 1-488)). The TQLPP segment in hTPO was structurally aligned with each of the TQLPP segments of the modeled proteins, after which, hTPO was removed resulting in the complex of TN1 with the modeled proteins following the methods mentioned for Spike above. The equilibrated structures of these complexes show that TN1 stays firmly with these proteins without any structural clash. Further, to evaluate the shape complementarity of these three proteins and TN1, MaSIF was used to calculate binding scores as described above (<xref ref-type="supplementary-material" rid="SD1">Table S6</xref>).</p><p id="P30">It should also be noted that two additional human genes (GeneIDs 8028 and 57110) also have one TQLPP motif, but not in the RefSeq Select isoforms. Since no structure or structural prediction was available for these proteins, they were excluded from further analysis.</p><p id="P31">For the ELDKY sequence motif, 6 additional representative isoforms containing the complete motif were found, in addition to the human proteins identified by Epitopedia to contain 3D-mimics of the motif. Solved structures of the ELDKY motif were available for 3 of the proteins, while the others had AlphaFold2 3D models available. In all instances, the region corresponding to the ELDKY motif was extracted and structurally superimposed with Spike ELDKY (from PDB id 6XR8) with TM-align as previously described.</p></sec><sec id="S13"><title>Statistical analysis</title><p id="P32">Distributions were visualized as violin plots with <monospace>ggpubr</monospace> and <monospace>ggplot2</monospace>. Following Shapiro-Wilk normality testing, statistical analysis comparing the different distributions was performed using Mann-Whitney U with <italic>SciPy,</italic> followed by a simplified Bonferroni correction (alpha/n comparisons) when appropriate.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Table S1</label><media xlink:href="EMS132734-supplement-Table_S1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d32aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>TableS3</label><media xlink:href="EMS132734-supplement-TableS3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d32aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>TableS4</label><media xlink:href="EMS132734-supplement-TableS4.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d32aAdEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Supplementary Material</label><media xlink:href="EMS132734-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d32aAdEeB" position="anchor"/></supplementary-material></sec></body><back><ack id="S14"><title>Acknowledgments</title><p>We thank Dr. Sathibalan Ponniah (Immune Analytics LLC, Columbia, MD), Dr. Charles Dimitroff (Florida International University), Dr. Sixto Leal (University of Alabama - Birmingham), and Kevin Bennett (Florida International University) for discussions.</p><sec id="S15"><title>Funding</title><p>This work was partially supported by the National Science Foundation under Grant No. 2037374 (JNC, PB, VS, KM, GN, PC, AMM, JSL).</p></sec></ack><fn-group><fn id="FN1" fn-type="con"><p id="P33"><bold>Contributions:</bold></p><p id="P34">J.S.-L., J.N.-C., C.A.B., G.N., P.C., K.M., T.C., A.M.M., P.B., and V.S. designed the overall method and approach. J.S.-L., G.N., P.C., A.M.M., K.M. supervised the research. J.N.-C., C.A.B., and J.S.-L. identified molecular mimicry. P.B. and P.C. performed modeling. G.N. and V.S. performed MaSIF-search. J.N.-C., C.A.B., J.S.-L., P.C, G.N., P.B., and V.S. analyzed the data. M.S., J.N.-C., C.A.B., J.S.-L, V.S., and P.B. performed visualization. G.N. and J.S.-L. performed project administration. J.S.-L. and J.N.-C. acted as lead authors. C.A.B., G.N., P.C., K.M., T.C., A.M.M., P.B., and V.S. contributed to writing the manuscript. All authors read and commented the manuscript.</p></fn><fn id="FN2" fn-type="conflict"><p id="P35"><bold>Competing interests:</bold> Authors declare that they have no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>B</given-names></name></person-group><article-title>Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections</article-title><source>Front Immunol</source><year>2019</year><volume>0</volume><fpage>2631</fpage><pub-id pub-id-type="doi">10.3389/FIMMU.2019.02631</pub-id></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audia</surname><given-names>S</given-names></name><name><surname>Bonnotte</surname><given-names>B</given-names></name></person-group><article-title>Emerging Therapies in Immune Thrombocytopenia</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>1004</fpage><pub-id pub-id-type="doi">10.3390/jcm10051004</pub-id></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balbin</surname><given-names>CA</given-names></name><name><surname>Nunez-Castilla</surname><given-names>J</given-names></name><name><surname>Stebliankin</surname><given-names>V</given-names></name><name><surname>Baral</surname><given-names>P</given-names></name><name><surname>Sobhan</surname><given-names>M</given-names></name><name><surname>Cickovski</surname><given-names>T</given-names></name><name><surname>Mondal</surname><given-names>AM</given-names></name><name><surname>Narasimhan</surname><given-names>G</given-names></name><name><surname>Chapagain</surname><given-names>P</given-names></name><name><surname>Mathee</surname><given-names>K</given-names></name><name><surname>Siltberg-Liberles</surname><given-names>J</given-names></name></person-group><article-title>Epitopedia: identifying molecular mimicry between pathogens and known immune epitopes</article-title><source>BioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.08.26.457577</pub-id></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Gilliland</surname><given-names>G</given-names></name><name><surname>Bhat</surname><given-names>TN</given-names></name><name><surname>Weissig</surname><given-names>H</given-names></name><name><surname>Shindyalov</surname><given-names>IN</given-names></name><name><surname>Bourne</surname><given-names>PE</given-names></name></person-group><article-title>The Protein Data Bank</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><fpage>235</fpage><lpage>242</lpage></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Brooks</surname><given-names>CL</given-names></name><name><surname>Mackerell</surname><given-names>AD</given-names></name><name><surname>Nilsson</surname><given-names>L</given-names></name><name><surname>Petrella</surname><given-names>RJ</given-names></name><name><surname>Roux</surname><given-names>B</given-names></name><name><surname>Won</surname><given-names>Y</given-names></name><name><surname>Archontis</surname><given-names>G</given-names></name><name><surname>Bartels</surname><given-names>C</given-names></name><name><surname>Boresch</surname><given-names>S</given-names></name><etal/></person-group><article-title>CHARMM: the biomolecular simulation program</article-title><source>J Comput Chem</source><year>2009</year><volume>30</volume><fpage>1545</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1002/JCC.21287</pub-id></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Sterling</surname><given-names>SM</given-names></name><name><surname>Walsh</surname><given-names>RM</given-names></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Rits-Volloch</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title><source>Science</source><year>2020</year><fpage>369</fpage><pub-id pub-id-type="doi">10.1126/science.abd4251</pub-id></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerutti</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Gorman</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Reddem</surname><given-names>ER</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Bahna</surname><given-names>F</given-names></name><name><surname>Bimela</surname><given-names>J</given-names></name><etal/></person-group><article-title>Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>819</fpage><lpage>833</lpage><elocation-id>e7</elocation-id><pub-id pub-id-type="doi">10.1016/J.CHOM.2021.03.005</pub-id></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chivukula</surname><given-names>RR</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Leung</surname><given-names>HM</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Shamseldin</surname><given-names>HE</given-names></name><name><surname>Taylor</surname><given-names>MS</given-names></name><name><surname>Dougherty</surname><given-names>GW</given-names></name><name><surname>Zariwala</surname><given-names>MA</given-names></name><name><surname>Carson</surname><given-names>J</given-names></name><name><surname>Daniels</surname><given-names>LA</given-names></name><etal/></person-group><article-title>A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>244</fpage><pub-id pub-id-type="doi">10.1038/S41591-019-0730-X</pub-id></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Frank</surname><given-names>M</given-names></name><name><surname>Woo</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Yeom</surname><given-names>MS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Seok</surname><given-names>C</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><article-title>Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane</article-title><source>J Chem Theory Comput</source><year>2021</year><volume>17</volume><fpage>2479</fpage><lpage>2487</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.0c01144</pub-id></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>P</given-names></name><name><surname>Rabold</surname><given-names>EM</given-names></name><name><surname>Laws</surname><given-names>RL</given-names></name><name><surname>Conners</surname><given-names>EE</given-names></name><name><surname>Gharpure</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Buono</surname><given-names>SA</given-names></name><name><surname>Dasu</surname><given-names>T</given-names></name><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><name><surname>Westergaard</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa799</pub-id></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>J</given-names></name><name><surname>Krawczyk</surname><given-names>K</given-names></name><name><surname>Leem</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Georges</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name></person-group><article-title>SAbDab: the structural antibody database</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><fpage>D1140</fpage><lpage>D1146</lpage><pub-id pub-id-type="doi">10.1093/NAR/GKT1043</pub-id></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essmann</surname><given-names>U</given-names></name><name><surname>Perera</surname><given-names>L</given-names></name><name><surname>Berkowitz</surname><given-names>ML</given-names></name><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>LG</given-names></name></person-group><article-title>A smooth particle mesh Ewald method</article-title><source>J Chem Phys</source><year>1995</year><volume>103</volume><fpage>8577</fpage><lpage>8593</lpage><pub-id pub-id-type="doi">10.1063/1.470117</pub-id></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feese</surname><given-names>MD</given-names></name><name><surname>Tamada</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Hirose</surname><given-names>M</given-names></name><name><surname>Matsukura</surname><given-names>Y</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Watarai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>1816</fpage><lpage>1821</lpage><pub-id pub-id-type="doi">10.1073/pnas.0308530100</pub-id></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RD</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Coggill</surname><given-names>P</given-names></name><name><surname>Eberhardt</surname><given-names>RY</given-names></name><name><surname>Eddy</surname><given-names>SR</given-names></name><name><surname>Heger</surname><given-names>A</given-names></name><name><surname>Hetherington</surname><given-names>K</given-names></name><name><surname>Holm</surname><given-names>L</given-names></name><name><surname>Mistry</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pfam: the protein families database</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><fpage>D222</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1223</pub-id></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraley</surname><given-names>E</given-names></name><name><surname>LeMaster</surname><given-names>C</given-names></name><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Khanal</surname><given-names>S</given-names></name><name><surname>Selvarangan</surname><given-names>R</given-names></name><name><surname>Bradley</surname><given-names>T</given-names></name></person-group><article-title>Cross-reactive antibody immunity against SARS-CoV-2 in children and adults</article-title><source>Cell Mol Immunol 2021 187</source><year>2021</year><volume>18</volume><fpage>1826</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1038/s41423-021-00700-0</pub-id></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>SH</given-names></name></person-group><article-title>The Role of cGMP-dependent Protein Kinase in Controlling Cardiomyocyte cGMP</article-title><source>Circ Res</source><year>2010</year><volume>107</volume><fpage>1164</fpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.233239</pub-id></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>SH</given-names></name><name><surname>Busch</surname><given-names>JL</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name></person-group><article-title>cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action</article-title><source>Pharmacol Rev</source><year>2010</year><volume>62</volume><fpage>525</fpage><pub-id pub-id-type="doi">10.1124/PR.110.002907</pub-id></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainza</surname><given-names>P</given-names></name><name><surname>Sverrisson</surname><given-names>F</given-names></name><name><surname>Monti</surname><given-names>F</given-names></name><name><surname>Rodolà</surname><given-names>E</given-names></name><name><surname>Boscaini</surname><given-names>D</given-names></name><name><surname>Bronstein</surname><given-names>MM</given-names></name><name><surname>Correia</surname><given-names>BE</given-names></name></person-group><article-title>Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning</article-title><source>Nat Methods 2019 172</source><year>2019</year><volume>17</volume><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0666-6</pub-id></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getts</surname><given-names>DR</given-names></name><name><surname>Chastain</surname><given-names>EM</given-names></name><name><surname>Terry</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group><article-title>Virus infection, antiviral immunity, and autoimmunity</article-title><source>Immunol Rev</source><year>2013</year><volume>255</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1111/IMR.12091</pub-id></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greinacher</surname><given-names>A</given-names></name><name><surname>Thiele</surname><given-names>T</given-names></name><name><surname>Warkentin</surname><given-names>TE</given-names></name><name><surname>Weisser</surname><given-names>K</given-names></name><name><surname>Kyrle</surname><given-names>PA</given-names></name><name><surname>Eichinger</surname><given-names>S</given-names></name></person-group><article-title>Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>2092</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1056/nejmoa2104840</pub-id></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Yu</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name></person-group><article-title>Kidney involvement in COVID-19 and its treatments</article-title><source>J Med Virol</source><year>2021</year><volume>93</volume><fpage>1387</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1002/jmv.26653</pub-id></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>JM</given-names></name><name><surname>Ansteatt</surname><given-names>KT</given-names></name><name><surname>Roberts</surname><given-names>JC</given-names></name><name><surname>Kamatam</surname><given-names>S</given-names></name><name><surname>Foong</surname><given-names>KS</given-names></name><name><surname>Labayog</surname><given-names>JMS</given-names></name><name><surname>Tarantino</surname><given-names>MD</given-names></name></person-group><article-title>Severe, refractory immune thrombocytopenia occurring after sars-cov-2 vaccine</article-title><source>J Blood Med</source><year>2021</year><volume>12</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.2147/JBM.S307047</pub-id></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodcroft</surname><given-names>EB</given-names></name></person-group><article-title>CoVariants: SARS-CoV-2 Mutations and Variants of Interest</article-title><year>2021</year><comment>[WWW Document]</comment></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><article-title>VMD: Visual molecular dynamics</article-title><source>J Mol Graph</source><year>1996</year><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Iyer</surname><given-names>VG</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><article-title>CHARMM-GUI: A web-based graphical user interface for CHARMM</article-title><source>J Comput Chem</source><year>2008</year><volume>29</volume><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1002/jcc.20945</pub-id></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Zídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nat 2021</source><year>2021</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanduc</surname><given-names>D</given-names></name></person-group><article-title>Thromboses and Hemostasis Disorders Associated with Coronavirus Disease 2019: The Possible Causal Role of Cross-Reactivity and Immunological Imprinting</article-title><source>Glob Med Genet</source><year>2021</year><pub-id pub-id-type="doi">10.1055/s-0041-1731068</pub-id></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Furumichi</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Ishiguro-Watanabe</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name></person-group><article-title>KEGG: integrating viruses and cellular organisms</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><fpage>D545</fpage><lpage>D551</lpage><pub-id pub-id-type="doi">10.1093/NAR/GKAA970</pub-id></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuter</surname><given-names>DJ</given-names></name></person-group><article-title>The biology of thrombopoietin and thrombopoietin receptor agonists</article-title><source>Int J Hematol 2013 981</source><year>2013</year><volume>98</volume><fpage>10</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/S12185-013-1382-0</pub-id></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Swails</surname><given-names>JM</given-names></name><name><surname>Yeom</surname><given-names>MS</given-names></name><name><surname>Eastman</surname><given-names>PK</given-names></name><name><surname>Lemkul</surname><given-names>JA</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Buckner</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>JC</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field</article-title><source>J Chem Theory Comput</source><year>2016</year><volume>12</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00935</pub-id></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients</article-title><source>Cell Mol Immunol 2020 1710</source><year>2020</year><volume>17</volume><fpage>1095</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-00523-5</pub-id></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Feil</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>RD</given-names></name><name><surname>Eigenthaler</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01254-0</pub-id></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Brady</surname><given-names>WJ</given-names></name><name><surname>Koyfman</surname><given-names>A</given-names></name><name><surname>Gottlieb</surname><given-names>M</given-names></name></person-group><article-title>Cardiovascular complications in COVID-19</article-title><source>Am J Emerg Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ajem.2020.04.048</pub-id></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrama</surname><given-names>D</given-names></name><name><surname>Mahita</surname><given-names>J</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name></person-group><article-title>Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens</article-title><source>EBioMedicine</source><year>2022</year><volume>75</volume><elocation-id>103807</elocation-id><pub-id pub-id-type="doi">10.1016/J.EBIOM.2021.103807</pub-id></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Thrombocytopenia and thrombosis in hospitalized patients with COVID-19</article-title><source>J Hematol Oncol</source><year>2020</year><pub-id pub-id-type="doi">10.1186/s13045-020-01003-z</pub-id></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazy</surname><given-names>I</given-names></name><name><surname>Kelton</surname><given-names>JG</given-names></name><name><surname>Moore</surname><given-names>JC</given-names></name><name><surname>Clare</surname><given-names>R</given-names></name><name><surname>Horsewood</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Ivetic</surname><given-names>N</given-names></name><name><surname>D’Souza</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Arnold</surname><given-names>DM</given-names></name></person-group><article-title>Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia</article-title><source>Br J Haematol</source><year>2018</year><volume>181</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1111/BJH.15165</pub-id></element-citation></ref><ref id="R38"><element-citation publication-type="web"><source>NCBI RefSeq Select</source><comment>[WWW Document], n.d URL <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/refseq/refseq_select/">https://www.ncbi.nlm.nih.gov/refseq/refseq_select/</ext-link></comment></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiga</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>DW</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lewis</surname><given-names>DB</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><article-title>COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives</article-title><source>Nat Rev Cardiol 2020 179</source><year>2020</year><volume>17</volume><fpage>543</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-0413-9</pub-id></element-citation></ref><ref id="R40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosé</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><article-title>Constant pressure molecular dynamics for molecular systems</article-title><source>Mol Phys</source><year>1983</year><volume>50</volume><fpage>1055</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1080/00268978300102851</pub-id></element-citation></ref><ref id="R41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patone</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>XW</given-names></name><name><surname>Handunnetthi</surname><given-names>L</given-names></name><name><surname>Dixon</surname><given-names>S</given-names></name><name><surname>Zaccardi</surname><given-names>F</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Watkinson</surname><given-names>P</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Harnden</surname><given-names>A</given-names></name><name><surname>Coupland</surname><given-names>CAC</given-names></name><etal/></person-group><article-title>Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection</article-title><source>Nat Med</source><year>2021</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01630-0</pub-id></element-citation></ref><ref id="R42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>JC</given-names></name><name><surname>Braun</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gumbart</surname><given-names>J</given-names></name><name><surname>Tajkhorshid</surname><given-names>E</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name><name><surname>Chipot</surname><given-names>C</given-names></name><name><surname>Skeel</surname><given-names>RD</given-names></name><name><surname>Kalé</surname><given-names>L</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><article-title>Scalable molecular dynamics with NAMD</article-title><source>J Comput Chem</source><year>2005</year><volume>26</volume><fpage>1781</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1002/jcc.20289</pub-id></element-citation></ref><ref id="R43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Sauer</surname><given-names>MM</given-names></name><name><surname>Czudnochowski</surname><given-names>N</given-names></name><name><surname>Low</surname><given-names>JS</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Housley</surname><given-names>MP</given-names></name><name><surname>Noack</surname><given-names>J</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><etal/></person-group><article-title>Broad betacoronavirus neutralization by a stem helix-specific human antibody</article-title><source>Science</source><year>2021</year><pub-id pub-id-type="doi">10.1126/SCIENCE.ABJ3321</pub-id></element-citation></ref><ref id="R44"><element-citation publication-type="web"><collab>Respiratory Syncytial Virus (RSV)</collab><source>NIH: National Institute of Allergy and Infectious Diseases</source><comment>n.d, [WWW Document], URL <ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv">https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv</ext-link></comment></element-citation></ref><ref id="R45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryckaert</surname><given-names>JP</given-names></name><name><surname>Ciccotti</surname><given-names>G</given-names></name><name><surname>Berendsen</surname><given-names>HJC</given-names></name></person-group><article-title>Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes</article-title><source>J Comput Phys</source><year>1977</year><volume>23</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/0021-9991(77)90098-5</pub-id></element-citation></ref><ref id="R46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>P</given-names></name><name><surname>Fitzpatrick</surname><given-names>MC</given-names></name><name><surname>Zimmer</surname><given-names>CF</given-names></name><name><surname>Abdollahi</surname><given-names>E</given-names></name><name><surname>Juden-Kelly</surname><given-names>L</given-names></name><name><surname>Moghadas</surname><given-names>SM</given-names></name><name><surname>Singer</surname><given-names>BH</given-names></name><name><surname>Galvani</surname><given-names>AP</given-names></name></person-group><article-title>Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><fpage>118</fpage><pub-id pub-id-type="doi">10.1073/PNAS.2109229118/-/DCSUPPLEMENTAL</pub-id></element-citation></ref><ref id="R47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanner</surname><given-names>MF</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name><name><surname>Spehner</surname><given-names>JC</given-names></name></person-group><article-title>Reduced surface: an efficient way to compute molecular surfaces - PubMed</article-title><source>Biopolymers</source><year>1996</year><volume>38</volume><fpage>305</fpage><lpage>320</lpage></element-citation></ref><ref id="R48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauzeau</surname><given-names>V</given-names></name><name><surname>Le Jeune</surname><given-names>H</given-names></name><name><surname>Cario-Toumaniantz</surname><given-names>C</given-names></name><name><surname>Smolenski</surname><given-names>A</given-names></name><name><surname>Lohmann</surname><given-names>SM</given-names></name><name><surname>Bertoglio</surname><given-names>J</given-names></name><name><surname>Chardin</surname><given-names>P</given-names></name><name><surname>Pacaud</surname><given-names>P</given-names></name><name><surname>Loirand</surname><given-names>G</given-names></name></person-group><article-title>Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>21722</fpage><lpage>21729</lpage><pub-id pub-id-type="doi">10.1074/JBC.M000753200</pub-id></element-citation></ref><ref id="R49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saviano</surname><given-names>A</given-names></name><name><surname>Wrensch</surname><given-names>F</given-names></name><name><surname>Ghany</surname><given-names>MG</given-names></name><name><surname>Baumert</surname><given-names>TF</given-names></name></person-group><article-title>Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>1088</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1002/HEP.31684</pub-id></element-citation></ref><ref id="R50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrödinger</surname><given-names>L</given-names></name></person-group><article-title>The PyMOL Molecular Graphics System, Version 2 5 0</article-title><year>2015</year></element-citation></ref><ref id="R51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>NH</given-names></name><name><surname>Sørvoll</surname><given-names>IH</given-names></name><name><surname>Michelsen</surname><given-names>AE</given-names></name><name><surname>Munthe</surname><given-names>LA</given-names></name><name><surname>Lund-Johansen</surname><given-names>F</given-names></name><name><surname>Ahlen</surname><given-names>MT</given-names></name><name><surname>Wiedmann</surname><given-names>M</given-names></name><name><surname>Aamodt</surname><given-names>A-H</given-names></name><name><surname>Skattør</surname><given-names>TH</given-names></name><name><surname>Tjønnfjord</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination</article-title><source>N Engl J Med</source><year>2021</year><elocation-id>NEJMoa2104882</elocation-id><pub-id pub-id-type="doi">10.1056/NEJMoa2104882</pub-id></element-citation></ref><ref id="R52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id></element-citation></ref><ref id="R53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>N</given-names></name></person-group><article-title>Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis</article-title><source>BMC Infect Dis</source><year>2021</year><volume>21</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.1186/S12879-021-06369-0</pub-id></element-citation></ref><ref id="R54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebliankin</surname><given-names>V</given-names></name><name><surname>Baral</surname><given-names>P</given-names></name><name><surname>Balbin</surname><given-names>C</given-names></name><name><surname>Nunez-Castilla</surname><given-names>J</given-names></name><name><surname>Sobhan</surname><given-names>M</given-names></name><name><surname>Cickovski</surname><given-names>T</given-names></name><name><surname>Mohan Mondal</surname><given-names>A</given-names></name><name><surname>Siltberg-Liberles</surname><given-names>J</given-names></name><name><surname>Chapagain</surname><given-names>P</given-names></name><name><surname>Mathee</surname><given-names>K</given-names></name><etal/></person-group><article-title>EMoMiS: A Pipeline for Epitope-based Molecular Mimicry Search in Protein Structures with Applications to SARS-CoV-2</article-title><source>BioRxiv</source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.02.05.479274</pub-id></element-citation></ref><ref id="R55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoddard</surname><given-names>CI</given-names></name><name><surname>Galloway</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Shipley</surname><given-names>MM</given-names></name><name><surname>Sung</surname><given-names>K</given-names></name><name><surname>Itell</surname><given-names>HL</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Logue</surname><given-names>JK</given-names></name><name><surname>Magedson</surname><given-names>A</given-names></name><name><surname>Garrett</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs</article-title><source>Cell Rep</source><year>2021</year><volume>35</volume><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109164</pub-id></element-citation></ref><ref id="R56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szent-Györgyi</surname><given-names>AG</given-names></name></person-group><article-title>Calcium regulation of muscle contraction</article-title><source>Biophys J</source><year>1975</year><volume>15</volume><fpage>707</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(75)85849-8</pub-id></element-citation></ref><ref id="R57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>T</given-names></name><name><surname>Kuwaki</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Watarai</surname><given-names>H</given-names></name><name><surname>Inagaki</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><name><surname>Ogami</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin</article-title><source>Stem Cells</source><year>1998</year><volume>16</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/stem.160054</pub-id></element-citation></ref><ref id="R58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>WR</given-names></name></person-group><article-title>Residual colours: a proposal for aminochromography</article-title><source>Protein Eng</source><year>1997</year><volume>10</volume><fpage>743</fpage><lpage>746</lpage></element-citation></ref><ref id="R59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Zídek</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Laydon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly accurate protein structure prediction for the human proteome</article-title><source>Nat</source><year>2021</year><volume>2021</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03828-1</pub-id></element-citation></ref><ref id="R60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>LN</given-names></name><name><surname>Defour</surname><given-names>J-P</given-names></name><name><surname>Pecquet</surname><given-names>C</given-names></name><name><surname>Constantinescu</surname><given-names>SN</given-names></name></person-group><article-title>The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin</article-title><source>Front Endocrinol (Lausanne)</source><year>2017</year><volume>8</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.3389/FENDO.2017.00059</pub-id></element-citation></ref><ref id="R61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vita</surname><given-names>R</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Overton</surname><given-names>JA</given-names></name><name><surname>Dhanda</surname><given-names>SK</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Cantrell</surname><given-names>JR</given-names></name><name><surname>Wheeler</surname><given-names>DK</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name></person-group><article-title>The Immune Epitope Database (IEDB): 2018 update</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>D339</fpage><lpage>D343</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1006</pub-id></element-citation></ref><ref id="R62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>C</given-names></name><name><surname>Esmail</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Knauer</surname><given-names>MJ</given-names></name><name><surname>Ackloo</surname><given-names>S</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Lowes</surname><given-names>L</given-names></name><name><surname>Stogios</surname><given-names>P</given-names></name><name><surname>Seitova</surname><given-names>A</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><pub-id pub-id-type="doi">10.1172/jci.insight.148855</pub-id></element-citation></ref><ref id="R63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title><source>JAMA - J Am Med Assoc</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="R64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>EY</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Huck</surname><given-names>JD</given-names></name><name><surname>Jaycox</surname><given-names>JR</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diverse functional autoantibodies in patients with COVID-19</article-title><source>Nat 2021 5957866</source><year>2021</year><volume>595</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03631-y</pub-id></element-citation></ref><ref id="R65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>AM</given-names></name><name><surname>Procter</surname><given-names>JB</given-names></name><name><surname>Martin</surname><given-names>DMA</given-names></name><name><surname>Clamp</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>GJ</given-names></name></person-group><article-title>Jalview Version 2--a multiple sequence alignment editor and analysis workbench</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1189</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp033</pub-id></element-citation></ref><ref id="R66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>A</given-names></name><name><surname>Raj</surname><given-names>K</given-names></name><name><surname>Gogia</surname><given-names>P</given-names></name><name><surname>Gahona</surname><given-names>CCT</given-names></name><name><surname>Porcelli</surname><given-names>M</given-names></name></person-group><article-title>Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19</article-title><source>Cureus</source><year>2021</year><volume>13</volume><pub-id pub-id-type="doi">10.7759/CUREUS.14505</pub-id></element-citation></ref><ref id="R67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Stoesser</surname><given-names>N</given-names></name><name><surname>Maddox</surname><given-names>T</given-names></name><name><surname>Lorenzi</surname><given-names>L</given-names></name><name><surname>Studley</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name><name><surname>Newton</surname><given-names>JN</given-names></name><name><surname>Farrar</surname><given-names>J</given-names></name><name><surname>Diamond</surname><given-names>I</given-names></name><etal/></person-group><article-title>Anti-spike antibody response to natural SARS-CoV-2 infection in the general population</article-title><source>Nat Commun 2021 121</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-26479-2</pub-id></element-citation></ref><ref id="R68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Park</surname><given-names>T</given-names></name><name><surname>Tanveer</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Kern</surname><given-names>NR</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Yeom</surname><given-names>MS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><etal/></person-group><article-title>Developing a fully glycosylated full-length SARS-COV-2 spike protein model in a viral membrane</article-title><source>J Phys Chem B</source><year>2020</year><volume>124</volume><fpage>7128</fpage><lpage>7137</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.0c04553</pub-id></element-citation></ref><ref id="R69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1126/SCIENCE.ABB2507</pub-id></element-citation></ref><ref id="R70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Bowe</surname><given-names>B</given-names></name><name><surname>Al-Aly</surname><given-names>Z</given-names></name></person-group><article-title>Long-term cardiovascular outcomes of COVID-19</article-title><source>Nat Med</source><year>2022</year><volume>2022</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01689-3</pub-id></element-citation></ref><ref id="R71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Lillicrap</surname><given-names>D</given-names></name></person-group><article-title>Thrombocytopenia and its association with mortality in patients with COVID-19</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><fpage>1469</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1111/jth.14848</pub-id></element-citation></ref><ref id="R72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Skolnick</surname><given-names>J</given-names></name></person-group><article-title>TM-align: a protein structure alignment algorithm based on the TM-score</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>2302</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1093/NAR/GKI524</pub-id></element-citation></ref><ref id="R73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>195</fpage><pub-id pub-id-type="doi">10.3389/FPHAR.2020.00195/BIBTEX</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Molecular mimicry with autoimmune potential across SARS-CoV-2 Spike.</title><p>(a) Overview of molecular mimics (solid arrow: 3D-mimic, dashed arrow: AF-3D-mimic) for Spike in the linear sequence showing Spike domains (NTD: N-terminus domain of S1 subunit, RDB: receptor binding domain of S1 subunit, CTD: C-terminus domain of S1 subunit, S2: S2 domain) as predicted by Pfam (Finn et al., 2014) based on the NCBI reference sequence (YP:009724390.1). (b) Surface representation of Spike (PDB id: 6XR8 (Cai et al., 2020)) colored by subunit with residues colored by number of occurrences in a molecular mimic (blue: 1, green: 2, purple: 3, orange: 4 or more). Structural visualization generated with PyMOL (<xref ref-type="bibr" rid="R50">Schrödinger, 2015</xref>). (c) The number of occurrences of the sequence motif in human RefSeq Select isoforms arranged in order from the N-terminus to the C-terminus and colored by primary secondary structure element based on Spike PDB id 6XR8.</p></caption><graphic xlink:href="EMS132734-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Structural mimicry between a TQLPP motif in SARS-CoV-2 Spike and an antibody binding epitope in thrombopoietin.</title><p>(<bold>a</bold>) Pairwise sequence alignment for the TQLPP motif in the epitope for human thrombopoietin (hTPO, IEDB Epitope ID: 920946) and Spike, colored by Taylor (Taylor, 1997) for sites with ≥ 50% conservation in the amino acid property (<xref ref-type="bibr" rid="R65">Waterhouse et al., 2009</xref>). The region of molecular mimicry is highlighted in the red dashed box. Surface representation of Spike from (<bold>b</bold>) the top and (<bold>c</bold>) the side, with Spike trimer (PDB id: 6XR8 (Cai et al., 2020)) colored by subunit and red indicating the location of the TQLPP epitope fragment, illustrating the surface accessibility of TQLPP. (<bold>d</bold>) Surface representation shown for hTPO (gray, PDB id: 1V7M (Feese et al., 2004)) and its TN1 antibody (blue) with the TQLPP motif (red) at the interface. (<bold>e</bold>) TM-align generated structural alignment for TQLPP in Spike (beige) and hTPO (gray), with RMSD = 0.61 Å. (<bold>f</bold>) Violin plots of RMSD values resulting from the comparison of the TQLPP region in 60 Spike structures vs TQLPP in two hTPO structures (PDB ids: 1V7M and 1V7N, chain X for both (<xref ref-type="bibr" rid="R13">Feese et al., 2004</xref>)). Statistical analysis with Mann-Whitney U reveals no statistical significance between the sets. Box plots, bounded by the 1st and 3rd quartiles, show median value (horizontal solid bold line), vertical lines (whiskers) represent 1.5 × IQR, while outliers are marked as black points. For further details, see methods. Alignment representations were generated with Jalview (Waterhouse et al., 2009) and structural visualizations were generated with PyMOL (<xref ref-type="bibr" rid="R50">Schrödinger, 2015</xref>).</p></caption><graphic xlink:href="EMS132734-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Binding of SARS-CoV-2 Spike to TN1 Fab antibody. Equilibrated structure (1 ns) of the modeled TN1 Fab antibody (blue, PDB id: 1V7M) complexed with Spike trimer model shown from (<bold>a</bold>) the side and (<bold>b</bold>) the top, with TQLPP shown as red spheres. (<bold>c</bold>) The Spike NTD (beige) and TN1 Fab complex used for MD simulations (200 ns), with adjacent glycans at N17 and N74 highlighted in purple. The representative amino acids contributing to hydrogen bonds (dashed lines) during the last 50 ns of simulations for the (<bold>d</bold>) hTPO-TN1 and (<bold>e</bold>) Spike-TN1 complexes are highlighted as cyan sticks. (<bold>f</bold>) Violin plot showing the distribution of the MaSIF binding score values for randomly selected patch pairs (blue), the interacting region of Spike-antibody (yellow) and hTPO-TN1 (gray) complexes, and for modeled Spike-TN1 complexes across 40 Spike configurations (red). Statistical analysis with Mann-Whitney U shows that all pairwise comparisons except for Spike-Ab and hTPO-TN1 are significantly different after Bonferroni correction (<xref ref-type="supplementary-material" rid="SD1">Table S5</xref>). Box plots, bounded by the 1st and 3rd quartiles, show median value (horizontal solid bold line), vertical lines (whiskers) represent 1.5 × IQR, while outliers are marked as black points. For further details, see methods. Structural visualizations were generated with PyMOL (<xref ref-type="bibr" rid="R50">Schrödinger, 2015</xref>) and VMD (<xref ref-type="bibr" rid="R25">Humphrey et al., 1996</xref>).</p></caption><graphic xlink:href="EMS132734-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Predicted interaction patches between TN1 Fab antibody (PDB id: 1V7N) and the TQLPP motif. The best (lowest) binding score is shown for Spike (PDB id: 7LQV, chain A), hTPO (PDB id: 1V7N, chain X), NEK10 (Uniprot: Q6ZWH5), ALG12 (Uniprot: Q9BV10), and FCRL4 (Uniprot: Q96PJ5). For all, red indicates the TQLPP motif and blue dots represent the surface points included in the predicted MaSIF patches.</p></caption><graphic xlink:href="EMS132734-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Structural mimicry between an ELDKY motif in SARS-CoV-2 Spike and epitopes in 6 other proteins.</title><p>(<bold>a</bold>) Sequence alignment between SARS-CoV-2 Spike and the epitopes containing the 3D-mimicry motif for human kynureninase (hKYNU, IEDB Epitope ID: 1007556), respiratory syncytial virus fusion F0 glycoprotein (RSV F0, IEDB Epitope ID: 1087776), human cytoplasmic FMR1-interacting protein 1 (hCYFIP1, IEDB Epitope ID: 1346528), human tight junction-associated protein 1 (hTJAP1, IEDB Epitope ID: 1016424), human keratin type I cytoskeletal 18 (hKRT18, IEDB Epitope ID: 1331545), and human tropomyosin alpha-3 (hTPM3, IEDB Epitope ID: 938472). Residues in the molecular mimicry motifs are colored by Taylor (Taylor, 1997). The extended molecular mimicry region is highlighted by the orange dashed box. (<bold>b</bold>) Surface representation of Spike (PDB id: 6XR8) colored by subunit with ELDKY motif indicated in red. Surface representation of proteins (gray) with full or partial 3D-mimics of the ELDKY motif (red): (<bold>c</bold>) hKYNU (PDB id: 2HZP), (<bold>d</bold>) RSV F0 (PDB id: 6EAE), (<bold>e</bold>) hCYFIP1 (PDB id: 4N78), (f) hTJAP1 (Uniprot: Q5JTD0), (<bold>g</bold>) hKRT18 (Uniprot: P05783), (<bold>h</bold>) hTPM3 (Uniprot: P06753). Alignment representations were generated with Jalview (Waterhouse et al., 2009) and structural visualizations were generated with PyMOL (<xref ref-type="bibr" rid="R50">Schrödinger, 2015</xref>).</p></caption><graphic xlink:href="EMS132734-f005"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>3D-mimics found for SARS-CoV-2 Spike</title></caption><table frame="box" rules="none"><thead><tr><th align="center" valign="top">Motif</th><th align="center" valign="top">Protein</th><th align="center" valign="top">Species</th><th align="center" valign="top">RMSD</th><th align="center" valign="top">Z-Score</th><th align="center" valign="top">EpiScore</th><th align="center" valign="top">PDB_chain</th></tr></thead><tbody><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>TQLPP</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Thrombopoietin</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.46 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.34</td><td align="center" valign="top" style="background-color:#f2f2f2">10.87</td><td align="center" valign="top" style="background-color:#f2f2f2">1V7N_X</td></tr><tr><td align="center" valign="top"><bold>QLPPA</bold></td><td align="center" valign="top">SMYD3 protein</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.38 Å</td><td align="center" valign="top">-1.42</td><td align="center" valign="top">13.16</td><td align="center" valign="top">5CCL_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>KNLRE</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Toll-like receptor 8</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.87 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-0.92</td><td align="center" valign="top" style="background-color:#f2f2f2">5.75</td><td align="center" valign="top" style="background-color:#f2f2f2">6WML_D</td></tr><tr><td align="center" valign="top"><bold>FTVEKG</bold></td><td align="center" valign="top">Pollen allergen Phl p2</td><td align="center" valign="top"><italic>Phleum pratense</italic></td><td align="center" valign="top">0.76 Å</td><td align="center" valign="top">-1.03</td><td align="center" valign="top">7.89</td><td align="center" valign="top">1WHP_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>GEVFN</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Integrin beta 1</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.63 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.16</td><td align="center" valign="top" style="background-color:#f2f2f2">7.94</td><td align="center" valign="top" style="background-color:#f2f2f2">7NWL_B</td></tr><tr><td align="center" valign="top"><bold>HAPAT</bold></td><td align="center" valign="top">Activator of 90 kDa heat shock protein ATPase homolog 1</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.74 Å</td><td align="center" valign="top">-1.05</td><td align="center" valign="top">6.76</td><td align="center" valign="top">7DME_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>YSTGS</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Argininosuccinate lyase</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.48 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.31</td><td align="center" valign="top" style="background-color:#f2f2f2">10.42</td><td align="center" valign="top" style="background-color:#f2f2f2">1 K62_B</td></tr><tr><td align="center" valign="top"><bold>EHVNN</bold></td><td align="center" valign="top">Casein kinase 2 alpha isoform</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.29 Å</td><td align="center" valign="top">-1.51</td><td align="center" valign="top">17.24</td><td align="center" valign="top">2ZJW_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>NLLLQ</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">DNA polymerase subunit gamma 1</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.57 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.22</td><td align="center" valign="top" style="background-color:#f2f2f2">8.77</td><td align="center" valign="top" style="background-color:#f2f2f2">5C51_A</td></tr><tr><td align="center" valign="top"><bold>LLQYG</bold></td><td align="center" valign="top">Ankyrin 1</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.20 Å</td><td align="center" valign="top">-1.60</td><td align="center" valign="top">25.00</td><td align="center" valign="top">1N11_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>LPDPS</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">BRCA1-A complex subunit BRE</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.32 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.48</td><td align="center" valign="top" style="background-color:#f2f2f2">15.62</td><td align="center" valign="top" style="background-color:#f2f2f2">6GVW_C</td></tr><tr><td align="center" valign="top"><bold>LPDPS</bold></td><td align="center" valign="top">Semaphorin 7a</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.84 Å</td><td align="center" valign="top">-0.91</td><td align="center" valign="top">5.95</td><td align="center" valign="top">3NVQ_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>DPSKP</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">60S ribosomal protein L3</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.10 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.70</td><td align="center" valign="top" style="background-color:#f2f2f2">50.00</td><td align="center" valign="top" style="background-color:#f2f2f2">6LU8_B</td></tr><tr><td align="center" valign="top"><bold>DPSKP</bold></td><td align="center" valign="top">Alanine and proline-rich secreted protein apa precursor</td><td align="center" valign="top"><italic>Mycobact erium tuberculo sis</italic></td><td align="center" valign="top">0.21 Å</td><td align="center" valign="top">-1.59</td><td align="center" valign="top">23.81</td><td align="center" valign="top">5ZXA_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>IAARD</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Talin</td><td align="center" valign="top" style="background-color:#f2f2f2"><italic>Mus musculus</italic></td><td align="center" valign="top" style="background-color:#f2f2f2">0.74 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.05</td><td align="center" valign="top" style="background-color:#f2f2f2">6.76</td><td align="center" valign="top" style="background-color:#f2f2f2">6R9T_A</td></tr><tr><td align="center" valign="top"><bold>GNCDV</bold></td><td align="center" valign="top">Tryptophan-tRNA ligase</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.91 Å</td><td align="center" valign="top">-0.88</td><td align="center" valign="top">5.49</td><td align="center" valign="top">105T_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>SFKEE</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Small subunit processome component 20 homolog</td><td align="center" valign="top" style="background-color:#f2f2f2">Human</td><td align="center" valign="top" style="background-color:#f2f2f2">0.32 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.48</td><td align="center" valign="top" style="background-color:#f2f2f2">15.62</td><td align="center" valign="top" style="background-color:#f2f2f2">7MQA_SP</td></tr><tr><td align="center" valign="top"><bold>EELDK</bold></td><td align="center" valign="top">Kynureninase</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.22 Å</td><td align="center" valign="top">-1.58</td><td align="center" valign="top">22.73</td><td align="center" valign="top">2HZP_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>ELDKY</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Fusion glycoprotein F0</td><td align="center" valign="top" style="background-color:#f2f2f2">Respiratory syncytial virus</td><td align="center" valign="top" style="background-color:#f2f2f2">0.12 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.68</td><td align="center" valign="top" style="background-color:#f2f2f2">41.67</td><td align="center" valign="top" style="background-color:#f2f2f2">6EAE_F</td></tr><tr><td align="center" valign="top"><bold>DKYFK</bold></td><td align="center" valign="top">Cytoplasmic FMR1-interacting protein 1</td><td align="center" valign="top">Human</td><td align="center" valign="top">0.14 Å</td><td align="center" valign="top">-1.66</td><td align="center" valign="top">35.71</td><td align="center" valign="top">4N78_A</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Human AF-3D-mimics for SARS-CoV-2 Spike</title></caption><table frame="box" rules="none"><thead><tr><th align="center" valign="top">Motif</th><th align="center" valign="top">Protein</th><th align="center" valign="top">RMSD</th><th align="center" valign="top">Z-Score</th><th align="center" valign="top">EpiScore</th><th align="center" valign="top">AlphaFold2 ID</th></tr></thead><tbody><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>NLLLQ</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Ankyrin 3</td><td align="center" valign="top" style="background-color:#f2f2f2">0.61 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.18</td><td align="center" valign="top" style="background-color:#f2f2f2">8.20</td><td align="center" valign="top" style="background-color:#f2f2f2">AF-Q12955-F1-model_v1_A</td></tr><tr><td align="center" valign="top"><bold>LLQYG</bold></td><td align="center" valign="top">Olfactory receptor 10Q1</td><td align="center" valign="top">0.66 Å</td><td align="center" valign="top">-1.13</td><td align="center" valign="top">7.58</td><td align="center" valign="top">AF-Q8NGQ4-F1-model_v1_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>TGIAV</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Phosphofructokinase</td><td align="center" valign="top" style="background-color:#f2f2f2">0.17 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.63</td><td align="center" valign="top" style="background-color:#f2f2f2">29.41</td><td align="center" valign="top" style="background-color:#f2f2f2">AF-P17858-F1-model_v1_A</td></tr><tr><td align="center" valign="top"><bold>TGIAV</bold></td><td align="center" valign="top">Low affinity immunoglobulin gamma Fc region receptor II-b</td><td align="center" valign="top">0.17 Å</td><td align="center" valign="top">-1.63</td><td align="center" valign="top">29.41</td><td align="center" valign="top">AF-P31995-F1-model_v1_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>KIQDSL</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Phosphorylase b kinase regulatory subunit beta</td><td align="center" valign="top" style="background-color:#f2f2f2">0.19 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.61</td><td align="center" valign="top" style="background-color:#f2f2f2">31.58</td><td align="center" valign="top" style="background-color:#f2f2f2">AF-Q93100-F1-model_v1_A</td></tr><tr><td align="center" valign="top"><bold>KIQDSL</bold></td><td align="center" valign="top">Long-chain-fatty-acid-CoA ligase 5</td><td align="center" valign="top">0.37 Å</td><td align="center" valign="top">-1.43</td><td align="center" valign="top">16.22</td><td align="center" valign="top">AF-Q9ULC5-F1-model_v1_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>VYDPL</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Actin-binding protein IPP</td><td align="center" valign="top" style="background-color:#f2f2f2">0.17 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.63</td><td align="center" valign="top" style="background-color:#f2f2f2">29.41</td><td align="center" valign="top" style="background-color:#f2f2f2">AF-Q9Y573-F1-model_v1_A</td></tr><tr><td align="center" valign="top"><bold>EELDK</bold></td><td align="center" valign="top">Tight junction-associated protein 1</td><td align="center" valign="top">0.20 Å</td><td align="center" valign="top">-1.60</td><td align="center" valign="top">25.00</td><td align="center" valign="top">AF-Q5JTD0-F1-model_v1_A</td></tr><tr><td align="center" valign="top" style="background-color:#f2f2f2"><bold>EELDKY</bold></td><td align="center" valign="top" style="background-color:#f2f2f2">Keratin, type I cytoskeletal 18</td><td align="center" valign="top" style="background-color:#f2f2f2">0.22 Å</td><td align="center" valign="top" style="background-color:#f2f2f2">-1.58</td><td align="center" valign="top" style="background-color:#f2f2f2">27.27</td><td align="center" valign="top" style="background-color:#f2f2f2">AF-P05783-F1-model_v1_A</td></tr><tr><td align="center" valign="top"><bold>ELDKY</bold></td><td align="center" valign="top">Tropomyosin alpha-3 chain</td><td align="center" valign="top">0.18 Å</td><td align="center" valign="top">-1.62</td><td align="center" valign="top">27.78</td><td align="center" valign="top">AF-P06753-F1-model_v1_A</td></tr></tbody></table></table-wrap></floats-group></article>